ReviewFrontiers in immunology2026
Anti-CD38 monoclonal antibodies in multiple myeloma and beyond: immunotherapeutic mechanisms, evidence maturity, and clinical positioning.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-CD38 monoclonal antibodies have become a central immunotherapeutic platform in multiple myeloma, where they have reshaped treatment across relapsed or refractory disease, frontline therapy, maintenance intensification, and minimal residual disease-oriented management. Their success in multiple myeloma has also stimulated broader development in immunoglobulin light-chain amyloidosis, selected hematologic malignancies, and humoral immune-mediated disorders. CD38 functions both as a surface target and as an ectoenzyme involved in nicotinamide adenine dinucleotide metabolism, calcium signaling, immune-cell regulation, and microenvironmental remodeling, providing a mechanistic basis for antibody-mediated cytotoxicity, immune modulation, and broader humoral immune intervention. This Review critically evaluates CD38 biology, Fc-mediated immune-effector mechanisms, immune remodeling, clinical evidence, resistance, safety, laboratory interferences, biomarker evidence, and clinical positioning of anti-CD38 antibodies, with multiple myeloma as the central reference disease. In immunoglobulin light-chain amyloidosis, daratumumab-based therapy has moved beyond myeloma-derived extrapolation and established a disease-specific framework integrating hematologic response, organ response, and survival outcomes. Beyond multiple myeloma, anti-CD38-based strategies have been investigated in light-chain amyloidosis, selected hematologic malignancies, autoimmune cytopenias, transplant-related alloimmunity, and other antibody-driven diseases. However, the strength of evidence differs substantially across these settings, and CD38 expression alone does not establish clinical benefit. Outside established plasma cell disorders, further development should therefore rely on disease-specific prospective evidence and careful assessment of safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.